DERM JOURNEY MED CORP revenue, earnings and financials

For the quarter ended June 30, 2026, JOURNEY MED CORP reported revenue of $18.5M (up 23.3% from a year earlier), net income of −$312K and diluted EPS of −$0.01; over the last four quarters revenue was $68.2M and net income −$6.10M; for the fiscal year ended December 2025 revenue was $61.9M, up 10.2% on the year before.

DERM annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $61.9M, gross profit n/a, operating income −$8.17M, net income −$11.4M (margin -18.5%), EPS −$0.47
• Fiscal year ended Dec 2024: revenue $56.1M, gross profit n/a, operating income −$13.7M, net income −$14.7M (margin -26.1%), EPS −$0.72
• Fiscal year ended Dec 2023: revenue $79.2M, gross profit n/a, operating income −$2.07M, net income −$3.85M (margin -4.9%), EPS −$0.21
• Fiscal year ended Dec 2022: revenue $73.7M, gross profit n/a, operating income −$27.5M, net income −$29.6M (margin -40.2%), EPS −$1.69
• Fiscal year ended Dec 2021: revenue $63.1M, gross profit n/a, operating income −$34.9M, net income −$44.0M (margin -69.7%), EPS −$4.32

DERM quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $18.5M (up 23.3% year over year), net income −$312K, EPS −$0.01
• Quarter ended Mar 31, 2026: revenue $16.0M (up 21.5% year over year), net income −$2.23M, EPS −$0.08
• Quarter ended Dec 31, 2025 (from the annual report): revenue $16.1M (up 18.1% year over year), net income −$1.25M, EPS −$0.04
• Quarter ended Sep 30, 2025: revenue $17.6M (up 20.5% year over year), net income −$2.32M, EPS −$0.09
• Quarter ended Jun 30, 2025: revenue $15.0M (up 1.0% year over year), net income −$3.80M, EPS −$0.16
• Quarter ended Mar 31, 2025: revenue $13.1M (up 0.8% year over year), net income −$4.07M, EPS −$0.18
• Quarter ended Dec 31, 2024 (from the annual report): revenue $13.6M (down 10.7% year over year), net income $1.52M, EPS $0.10
• Quarter ended Sep 30, 2024: revenue $14.6M (down 57.6% year over year), net income −$2.39M, EPS −$0.12
• Quarter ended Jun 30, 2024: revenue $14.9M (down 13.5% year over year), net income −$3.36M, EPS −$0.17
• Quarter ended Mar 31, 2024: revenue $13.0M (up 6.7% year over year), net income −$10.4M, EPS −$0.53
• Quarter ended Dec 31, 2023 (from the annual report): revenue $15.3M (down 4.4% year over year), net income −$2.14M, EPS $0.02
• Quarter ended Sep 30, 2023: revenue $34.5M (up 114.3% year over year), net income $16.8M, EPS $0.80
• Quarter ended Jun 30, 2023: revenue $17.2M (down 6.1% year over year), net income −$8.36M, EPS −$0.46
• Quarter ended Mar 31, 2023: revenue $12.2M (down 47.6% year over year), net income −$10.1M, EPS −$0.57
• Quarter ended Dec 31, 2022 (from the annual report): revenue $16.0M (down 8.9% year over year), net income −$10.6M, EPS −$0.61
• Quarter ended Sep 30, 2022: revenue $16.1M (down 17.8% year over year), net income −$10.1M, EPS −$0.57
• Quarter ended Jun 30, 2022: revenue $18.3M (up 19.6% year over year), net income −$7.53M, EPS −$0.43
• Quarter ended Mar 31, 2022: revenue $23.3M (up 117.3% year over year), net income −$1.38M, EPS −$0.08
• Quarter ended Dec 31, 2021 (from the annual report): revenue $17.5M, net income −$21.8M, EPS −$1.88
• Quarter ended Sep 30, 2021: revenue $19.6M, net income −$10.6M, EPS −$1.16

DERM cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$12.4M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$9.13M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $5.24M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$13.5M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$2.18M, share buybacks n/a

DERM balance sheet

• Jun 30, 2026: cash $25.6M, total assets $98.4M, total liabilities $66.2M, shareholders' equity $32.1M, long-term debt $20.5M
• Mar 31, 2026: cash $27.2M, total assets $91.5M, total liabilities $60.7M, shareholders' equity $30.8M, long-term debt $22.9M
• Dec 31, 2025: cash $24.1M, total assets $94.6M, total liabilities $62.7M, shareholders' equity $31.9M, long-term debt $25.3M
• Sep 30, 2025: cash $24.9M, total assets $85.2M, total liabilities $59.3M, shareholders' equity $25.9M, long-term debt $19.5M
• Jun 30, 2025: cash $20.3M, total assets $81.2M, total liabilities $61.9M, shareholders' equity $19.2M, long-term debt $21.4M
• Mar 31, 2025: cash $21.1M, total assets $85.0M, total liabilities $63.4M, shareholders' equity $21.5M, long-term debt $23.1M
• Dec 31, 2024: cash $20.3M, total assets $80.2M, total liabilities $60.2M, shareholders' equity $20.1M, long-term debt $24.9M
• Sep 30, 2024: cash $22.5M, total assets $64.0M, total liabilities $53.1M, shareholders' equity $10.9M, long-term debt $19.8M

What is DERM's revenue?

JOURNEY MED CORP reported $68.2M of revenue over its last four quarters, through June 30, 2026.

Is DERM profitable?

No. JOURNEY MED CORP lost $6.10M over the last four quarters.

What is DERM's EPS?

Diluted earnings per share over the last four quarters were −$0.22; −$0.01 in the latest quarter.

DERM ownership and insider trades · All stocks